Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

P158 Regional anesthesia techniques for a patient with scapular spine fracture
Nimma, Sindhuja

Poster displayed – Peripheral nerve blocks | September 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: A251.1-A251

10.1136/rapm-2025-esra.437 Get It

EP055 Combination regional anesthesia techniques for patients undergoing simultaneous double organ transplantation: case reports
West-Santos, Cassidy, Nimma, Sindhuja, Kalagara, Hari

ePoster session 2 – Station 3 | September 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: A81.1-A81

10.1136/rapm-2025-esra.127 Get It

EP043 Does the use of adductor canal blocks really affect knee osteoarthritis outcome scores among outpatient total knee arthroplasty patients?
Oseili, Ahmad, Naamani, Raji , Aboobacker, Sumayya, Wing, Clayton, Ubl, Daniel S. , Springer, Bryan D. , Ardon, Alberto E. , Aboobacker, Sumayya , Ledford, Cameron K.

ePoster session 2 – Station 1 | September 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: A73.2-A74

10.1136/rapm-2025-esra.115 Get It

Ablative Techniques for the Management of Osseous Spine Metastases: A Narrative Review
Pennington, Zach , Morris, Jonathan M. , Elsamadicy, Aladine A. , Lo, Sheng-Fu Larry , Schwab, Joseph H. , Sciubba, Daniel M. , Pennington, Zach , Sciubba, Daniel

Journal of Clinical Medicine | September 10, 2025 | Volume: 14 | Issue: 18 | Pages: 6358

10.3390/jcm14186358 | PMID 41010564 Get It

With continued improvements in systemic cancer therapies, there has been an increase in the survivorship of patients with spinal metastases. However, many patients with spinal metastases are frail and may not be able to tolerate the morbidity of open surgery. For these patients, percutaneous ablation techniques offer a minimally invasive approach that can facilitate local tumor control and pain relief. Here we describe the currently employed modalities—radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and laser interstitial thermal therapy (LITT)—summarize the clinical support for their use, and overview the relative risks and benefits for each. All these technologies offer to help improve local tumor control and improve oncologic pain associated with vertebral metastases, and they have become a staple of multidisciplinary spine metastasis care at many centers. As clinical experience with these technologies continues to grow, their use will likely become more widely adopted, and so understanding of their indications, risks, and benefits will become increasingly important to the practicing spine oncologist.
AI Based Clinical Decision-Making Tool for Neurologists in the Emergency Department
Gorenshtein, Alon , Fistel, Shiri, Sorka, Moran , Telman, Gregory , Winer, Raz, Peretz, Shlomi , Shelly, Shahar , Shahar, Shelly , Gorenshtein, Alon , Peretz, Shlomi , Aran, Dvir

Journal of Clinical Medicine | September 10, 2025 | Volume: 14 | Issue: 17 | Pages: 6333

10.3390/jcm14176333 | PMID 40944092 Get It

Introduction: We aimed to prove integration of advanced machine learning methods within a robust ensemble framework can enhance clinical decision-support for neurologists managing patients in the emergency department (ED). Methods: We engineered an ensemble framework leveraging the capabilities of the Gemini 1.5-pro-002 large language model (LLM). The model was enhanced using prompt engineering and retrieval-augmented generation (RAG). Predictive modeling achieved by combining eXtreme Gradient Boosting (XGBoost) and logistic regression for optimal accuracy in clinical decision-making. Key clinical outcomes, such as admission and mortality, were assessed. A random subset of 100 cases was reviewed by three senior neurologists to evaluate the alignment of the AI’s predictions with expert clinical judgment. Results: We retrospectively analyzed 1368 consecutive ED patients who underwent neurological consultations, assessing their clinical features, diagnostic tests, and admission outcomes. Patients admitted were typically older and had higher mortality rates, shorter intervals to neurological evaluation, and a higher incidence of acute stroke compared to those discharged. For the primary analysis (n = 250), the Neuro artificial intelligence (AI) model demonstrated significant performance metrics, achieving an area under the curve (AUC) of 0.88 for general admission predictions in comparison to actual outcomes, an AUC of 0.86 for neurological department admissions, 0.93 for long-term mortality risk, and 1 for 48 h mortality risk. Our Neuro AI model predictions showed a strong correlation with expert consensus (Pearson correlation 0.79, p < 0.001), indicating its ability to provide consistent support amid divergent clinical opinions. Conclusions: Our Neuro AI model accurately predicted hospital admissions (AUC = 0.88) and neurological department admissions (AUC = 0.86), demonstrating strong alignment with expert clinical judgment.
Optimizing dose rate to minimize delivery time in proton pencil beam dose‐driven continuous scanning
Han, Dong , Liu, Hongcheng , Tong, Jindong, Yaddanapudi, Sridhar , Park, Chunjoo, Tan, Jun , Beltran, Chris , Tan, Jun , Furutani, Keith, Beltran, Chris J , Yaddanapudi, Sridhar , Yang, Yu , Liang, Xiaoying , Tong, Jindong, Furutani, Keith M. , Lu, Bo, Tan, Jun

Medical Physics | September 10, 2025 | Volume: 52 | Issue: 9 | Pages: No page available

10.1002/mp.18098 | PMID 40926586 Get It

Abstract Background Dose‐driven continuous scanning (DDCS) enhances the efficiency and precision of proton pencil beam delivery by reducing beam pauses inherent in discrete spot scanning (DSS). However, current DDCS optimization studies using traveling salesman problem (TSP) formulations often rely on fixed beam intensity and computationally expensive interpolation for move spot generation, limiting efficiency and methodological robustness. Purpose This study introduces a Break Spot‐Guided (BSG) method, combined with two acceleration strategies—dose rate skipping and bounding—to optimize beam intensity while minimizing beam delivery time (BDT). In addition, a ‐method is proposed for efficient move spot generation, aiming to balance computational efficiency and dose calculation accuracy. Methods The BSG framework simplifies the original mixed‐integer nonlinear programming (MINLP) problem by transforming it into a series of TSP evaluations using break‐spot dose rates. The two acceleration strategies are integrated to reduce computational complexity. The ‐method is introduced to efficiently generate move spots without compromising dose fidelity. The performance of the BSG method, with and without the acceleration strategies, and the ‐method, was evaluated across multiple clinical cases. Results By jointly optimizing the scan path and dose rate, the proposed BSG‐S‐B method offered the most efficient delivery, achieving a 64% reduction in BDT compared to DSS and a 57% reduction compared to Liu's method in the prostate case. These gains were consistently observed across all cases. Utilizing acceleration strategies, BSG‐S‐B significantly reduced computation time from hours to minutes (e.g., from 10 525.7 to 108.5 s in the prostate case, and from 6202.4 to 129.8 s in the head‐and‐neck case). When combined with the ‐method, it reduced the number of move spots by more than 50%, while still ensuring dosimetric quality. Conclusions The proposed framework significantly improves computational efficiency, making scan path optimization with dose rate selection feasible for clinical DDCS delivery. The ‐method effectively reduces computational complexity while maintaining dose calculation accuracy, demonstrating strong potential for clinical adoption in proton therapy treatment planning.
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)
Parker, Terri L., Rosenthal, Adam , Sanchorawala, Vaishali , Landau, Heather , Kapoor, Prashant , Girnius, Saulius, Hagen, Patrick , Scott, Emma C. , Hoering, Antje , Durie, Brian G.M. , Orlowski, Robert Z. , Rosenthal, Adam N. , Landau, Heather , Campagnaro, Erica L , Hagen, Patrick , Orlowski, Robert Z. , Sanchorawala, Vaishali , Campagnaro, Erica , Neparidze, Natalia

Blood | September 9, 2025 | Volume: 146 | Issue: 21 | Pages: 2507-2516

10.1182/blood.2024027962 | PMID 40925099 Get It

Abstract Isatuximab is an immunoglobulin G1κ monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multicenter, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis. Isatuximab at 20 mg/kg was administered IV weekly during the first 28-day cycle, and then every other week during cycles 2 to 24. Forty-three patients were registered, with 35 patients being evaluable for response. The overall hematologic response rate was 77.1%, with 57% of patients achieving a very good partial response (VGPR) or better. The median time to partial response (PR) or better was 1.1 months. Renal response occurred in 50% (7/14) of patients with renal involvement, and cardiac response occurred in 57% (8/14) of patients who were evaluable utilizing N-terminal pro b-type natriuretic peptide (NT-proBNP) with cardiac involvement. The most common treatment-related grade ≥3 adverse events included lymphopenia (n = 3, 8.5%) and infection (n = 2, 6%). Isatuximab demonstrated substantial efficacy in previously treated patients with AL amyloidosis, and was associated with a good safety profile. This trial was registered at www.clinicaltrials.gov as #NCT03499808.
It’s Time to Consider How We Should Use Vasopressors, Rather Than Just Which We Should Use
Wieruszewski, Patrick M. , Jabaley, Craig S. , Wieruszewski, Patrick M , Jabaley, Craig S

Critical Care Explorations | September 9, 2025 | Volume: 7 | Issue: 9 | Pages: e1317

10.1097/cce.0000000000001317 | PMID 40924922 Get It

Asynchronous Development of B-cell and T-cell Post-transplant Lymphoproliferative Disorder in a Pediatric Heart Transplant Patient
Young, Amanda , Larson, Dan , Galardy, Paul J. , Ferdjallah, Asma, Galardy, Paul, Young, Amanda , Ferdjallah, Asmaa

Journal of Pediatric Hematology/Oncology | September 9, 2025 | Volume: 47 | Issue: 7 | Pages: e372-e376

10.1097/mph.0000000000003113 | PMID 40924961 Get It

Post-transplant lymphoproliferative disorder is a rare and serious complication of organ and stem cell transplant secondary to immunosuppressive therapies, most commonly of monomorphic B-cell subtype. Here we describe the first reported case of a pediatric heart transplant patient who developed both monomorphic B-cell and nondestructive PTLD with plasmacytic hyperplasia followed by an unrelated case of monomorphic T-cell and nondestructive PTLD with plasmacytic hyperplasia, which later relapsed. We detail the patient’s risk factors for development of PTLD and her successful treatment regimens. This case highlights the potential relationship between Epstein-Barr virus and/or cytomegalovirus and PTLD.